natgillin/translations-raw huggingface dataset:
A method for producing 1-(2-deoxy-2-halogeno-4-thio-β-D-arabinofuranosyl) cytosine represented by the following formula [14]: wherein R3 has the same meanings as those described below which comprises allowing a compound represented by the following formula [4]: wherein R1a represents a hydroxyl-protecting group; R2a represents a hydroxyl-protecting group; or R1a and R2a may together form an optionally substituted C1-3 alkylene group; and R3 represents a halogen atom, to react with a compound represented by the following formula [5]: 
Metoda za proizvodnju 1-(2-deoksi-2-halogeno-4-tio-β-D-arabinofuranozil) citozina koji je predstavljen sljedećom formulom [14]: gdje R3 ima ista značenja kao ona opisana ispod koja obuhvaća omogućavanje spoju koji je predstavljen sljedećom formulom [4]: gdje R1a predstavlja hidroksil-zaštitnu grupu; R2a predstavlja hidroksil-zaštitnu grupu; ili R1a i R2a mogu zajedno formirati po izboru supstituiranu C1-3 alkilensku grupu; i R3 predstavlja atom halogena, da reagira sa spojem koji je predstavljen sljedećom formulom [5]:
The method according to Claim 13, wherein the compound represented by the formula [11b] is isolated in the form of a solid. 
Metoda prema patentnom zahtjevu 13, gdje spoj predstavljen formulom [11b] je izoliran u obliku čvrste supstance.
The process of claim 2 wherein the solvent system is acetic acid. 
Postupak prema zahtjevu 2 gdje je sistem otapala octena kiselina.
The process of claim 2 wherein the solvent system is 90% acetic acid and 10% ethanol. 
Postupak prema zahtjevu 2 gdje je sistem otapala 90% octena kiselina i 10% etanol.
The process of claim 5 wherein the thiocarbonylating agent is 1-(2-oxopyridine-1-carbothioyl)pyridin-2-one. 
Postupak prema zahtjevu 5, gdje je sredstvo za tiokarbonilaciju 1-(2-oksopiridin-1-karbotioil)piridin-2-on.
The process of claim 6 wherein the organic solvent is DMA. 
Postupak prema zahtjevu 6 gdje je organsko otapalo DMA.
The process of claim 8, comprising reacting compound (VII) with an organomagnesium halide selected from the group consisting of a C1-8alkylmagnesium halide and a C5-7cycloalkylmagnesium halide; in the presence or absence of a lithium halide selected from the group consisting of lithium chloride, lithium bromide, and lithium iodide; followed by the addition of carbon dioxide gas; in an aprotic organic solvent selected from the group consisting of THF, 2-MeTHF, MTBE, CPME, and toluene; at a temperature of about 0 °C; to yield the corresponding carboxylic acid compound (1c). 
Postupak prema zahtjevu 8, koji obuhvaća reakciju spoja (VII) sa organomagnezijevim halogenidom koji je izabran iz grupe koja se sastoji od C1-8alkilmagnezijev halogenida i C5-7cikloalkilmagnezijev halogenida; u prisustvu ili odsustvu litij halogenida koji je izabran iz grupe koja se sastoji od litijevog klorida, litijevog bromida, i litijevog jododa; praćeno dodavanjem plina ugljikovog dioksida; u aprotonskom organskom otapalu koje je izabrano iz grupe koja se sastoji od THF, 2-MeTHF, MTBE, CPME, i toluena; na temperaturi od oko 0 °C; da bi se dobio odgovarajući spoj karboksilne kiseline (1c).
The process of claim 9 wherein the C1-8alkylmagnesium halide is a C1-8alkylmagnesium chloride or C1-8alkylmagnesium bromide. 
Postupak prema zahtjevu 9 gdje je C1-8alkilmagnezijev halogenid C1-8alkilmagnezijev klorid ili C1-8alkilmagnezijev bromid.
The process of claim 11 further comprising reacting compound (VII) with n- pentylmagnesium chloride; in the absence of a lithium halide; followed by the addition of carbon dioxide gas; in THF; at a temperature of about 0 °C; to yield the corresponding carboxylic acid compound (1c). 
Postupak prema zahtjevu 11, koji dalje obuhvaća reakciju spoja (VII) sa n-pentilmagnezij kloridom; u odsustvu litij halogenida; praćeno dodavanjem plina ugljikovog dioksida; u THF; na temperaturi od oko 0 °C; da bi se dobio odgovarajući spoj karboksilne kiseline (1c).
The process of claim 15 wherein the palladium catalyst is comprised of a phosphorus ligand that is dppf and a palladium metal compound that is palladium acetate. 
Postupak prema zahtjevu 15 gdje se paladijumov katalizator sastoji od fosfornog liganda koji je dppf i spoja metala paladija, a koji je paladij acetat.
The process of claim 17, further comprising reacting compound (1c) with a coupling agent that is CDI; wherein the aprotic or protic solvent is THF or toluene; at about room temperature; followed by the addition of methylamine; to yield the corresponding compound (X). 
Postupak prema zahtjevu 17, koji dalje obuhvaća spoj koji reagira (1c) sa sredstvom za spajanje koje je CDI; pri čemu je protonsko ili aprotonsko otapalo THF ili toluen; na približno sobnoj temperaturi; praćeno dodavanjem metilamina; da bi se dobio odgovarajući spoj (X).
The process of claim 18 wherein methylamine is added in its gaseous state. 
Postupak prema zahtjevu 18, pri čemu se metilamin dodaje u njegovom plinovitom stanju.
The process of claim 22, wherein step (1e) further comprises reacting compound (VII) with an organomagnesium halide selected from the group consisting of a C1-8alkylmagnesium halide and a C5-7cycloalkylmagnesium halide; in the presence or absence of a lithium halide selected from the group consisting of lithium chloride, lithium bromide, and lithium iodide; in an aprotic organic solvent selected from THF, 2-MeTHF, or toluene; at a temperature of about −50° C. to about 22° C.; followed by the addition of an C1-6alkyl chloroformate or C1-6alkyl cyanoformate; to yield the corresponding ester of formula (1e). 
Postupak prema zahtjevu 22, gdje korak (1e) dalje obuhvaća reakciju spoja (VII) sa organomagnezijevim halogenidom koji je izabran iz grupe koja se sastoji od C1-8alkilmagnezij halogenida i C5-7cikloalkilmagnezij halogenida; u prisustvu ili odsustvu litij halogenida koji je odabran iz grupe koja se sastoji od litij klorida, litij bromida, i litij jodida; u aprotonskom organskom otapalu koje se sastoji od THF, 2-MeTHF, ili toluena; na temperaturi oko -50 °C do oko 22 °C; nakon čega slijedi dodavanje C1-6alkil kloroformijata ili C1-6alkil cijanoformijata; da bi se dobio odgovarajući ester formule (1e).
The process of claim 30 wherein the palladium catalyst is Pd(P(t Bu3)2 and the base is 1.2 equivalents of DIPEA. 
Postupak prema zahtjevu 30 gdje je paladijev katalizator Pd(P(tBu3)2 i baza je 1.2 ekvivalenata DIPEA.
The process of claim 30 wherein the palladium catalyst is comprised of a phosphorus ligand, dppf, and a palladium metal compound that is palladium acetate; in the presence of DIPEA. 
Postupak prema zahtjevu 30, gdje se paladijev katalizator sastoji od fosfornog liganda, dppf, i spoja metala paladija koji je paladijev acetat; u prisustvu DIPEA.
The process of claim 35 wherein the protic or aprotic solvent is selected from the group consisting of THF, DMF, DMA, and ethanol, or a mixture thereof. 
Postupak prema zahtjevu 35, gdje je protonsko ili aprotonsko otapalo izabrano iz grupe koja se sastoji od THF, DMF, DMA, i etanola, ili njihove smjese.
The process of claim 36 wherein the methylamine is added in its gaseous state. 
Postupak prema zahtjevu 36, gdje se metilamin dodaje u njegovom plinovitom stanju.
The process as in claim 40 wherein norbornadiene, tetrabutylammonium bromide, and DABCO are present. 
Postupak prema zahtjevu 40, gdje se nalaze norbornadien, tetrabutilamonij bromid, i DABCO.
The process as in claim 41 wherein the organic solvent is butyronitrile or diglyme. 
Postupak prema zahtjevu 41, gdje je organsko otapalo butironitril ili diglim.
The process as in claim 44 wherein the palladium catalyst is Pd(P(tBu3)2 and the base is DIPEA. 
Postupak prema zahtjevu 44, gdje je paladijev katalizator Pd(P(tBu3)2 i baza je DIPEA.
The process as in claim 44 wherein methylamine is added in its gaseous state. 
Postupak prema zahtjevu 44, gdje se metilamin dodaje u njegovom plinovitom obliku.
Container assembly (1) according to claim 1 or 2, wherein at least two, preferably four of the sides of the polygonal cross-section comprise self-complementary interlocking features (30, 31). 
Sklop spremnika (1) prema zahtjevu 1 ili 2, naznačen time što najmanje dvije, te poželjno četiri strane poligonalnog poprečnog presjeka obuhvaćaju samo-komplementarne međusobno povezujuće značajke (30, 31).
Container assembly (1) according to any one of the preceding claims, wherein at least one of the chimes (4) provides at least one grip (16) for lifting and manipulating the assembly (1). 
Sklop spremnika (1) prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time što najmanje jedan od dijelova (4) osigurava najmanje jednu dršku (16) za podizanje i rukovanje sklopom (1).
Group of containers assemblies (1) according to claim 10, wherein the container assemblies (1) are stacked in layers on a pallet (25) and juxtaposed assemblies (1) in a layer abut at their polygonal cross-sections. 
Skupina sklopova spremnika (1) prema zahtjevu 10, naznačena time što su sklopovi spremnika (1) složeni u slojevima na paleti (25) i naslagani sklopovi (1) u sloju se naslanjaju na njihovim poligonalnim poprečnim presjecima.
Group of container assemblies (1) according to claim 11, wherein the container assemblies (1) in at least one, preferably all layers in the stack are urged together by means of an elongate tensioning element (26). 
Skupina sklopova spremnika (1) prema zahtjevu 11, naznačena time što su sklopovi spremnika (1) u najmanje jednom, poželjno u svim slojevima u snopu spojeni međusobno pomoću izduljenog zateznog elementa (26).
A method according to claim 1, comprising the step of comparing at least said determined conditioning parameter (PE(i)) with at last one predetermined reference magnitude GE(i) associated to a predetermined category of food-grade wood, and determining the belonging of the wooden part-components (2) to said predetermined category of food-grade wood on the basis of said comparison. 
Postupak sukladno patentnom zahtjevu 1, obuhvaća korak usporedbe parametara kondicioniranja s najmanje jednom unaprijed određenom referentnom magnitutdom GE(i) povezanom s predodređenom kategorijom drveta za uporabu u prehrambenoj industriji, i određivanje pripadnosti drvenog dijela (2) navedenoj predodređenoj kategoriji drveta za uporabu u prehrambenoj industriji na temelju navedene usporedbe.
An arrangement for cleaning a filter apparatus (3) arranged to a product gas line (2) of a product gas producing plant (1), the arrangement (100) comprising: 
Uređaj za čišćenje aparature za filtriranje (3) postavljene na cijev proizvodnog plina (2) postrojenja za proizvodnju proizvodnog plina (1), pri čemu uređaj (100) sadrži:
closing means (4) for separating a filter (5) of the filter apparatus (3) from the product gas line (2); 
sredstvo za zatvaranje (4) za razdvajanje filtera (5) aparature za filtriranje (3) od cijevi proizvodnog plina (2);
a channel system (6) connected to the filter (5) and comprising a feed channel (7) and a discharge channel (8); 
kanalni sustav (6) koji je spojen s filterom (5) i sadrži dovodni kanal (7) i odvodni kanal (8);
An arrangement as claimed in any one of the preceding claims, wherein the filter apparatus (3) comprises a plural number of parallel filters (5) grouped into at least two cleaning groups (16a, 16b) and in that the cleaning has been arranged to take place according to cleaning groups (16a, 16b). 
Uređaj prema bilo kojem od prethodnih zahtjeva, naznačen time da aparatura za filtriranje (3) sadrži velik broj paralelnih filtera (5) grupiranih u najmanje dvije skupine za čišćenje (16a, 16b) i time da je čišćenje izvedeno tako da se odvija prema skupinama za čišćenje (16a, 16b).
measuring oxygen content of the regeneration gas (RG) to be fed into the filter (5) and/or that has passed through the filter (5); and 
mjerenja sadržaja kisika regeneracijskog plina (RG), koji treba dovesti u filter (5) i/ili koji je prošao kroz filter (5); i
measuring the temperature of the regeneration gas (RG) to be fed into the filter (5) and/or that has passed through the filter (5); and 
mjerenja temperature regeneracijskog plina (RG), koji treba dovesti u filter (5) i/ili koji je prošao kroz filter (5); i
adjusting the temperature of the regeneration gas (RG) by changing, when necessary, the flow rate and/or composition of the control gas (CG). 
prilagođavanja temperature regeneracijskog plina (RG) mijenjanjem, ako je potrebno, stope protoka i/ili sastava kontrolnog plina (CG).
A method as claimed in claim 8 or 9, wherein the flow rate of the regeneration gas (RG) is at least equal to a normal product gas flow rate through the filter (5) or wherein the flow rate of the regeneration gas (RG) is lower than a normal product gas flow rate of the product gas through the filter (5). 
Postupak prema zahtjevu 8 ili 9, naznačen time da je stopa protoka regeneracijskog plina (RG) barem jednaka normalnoj stopi protoka proizvodnog plina kroz filter (5) ili time da je stopa protoka regeneracijskog plina (RG) niža od normalne stope protoka proizvodnog plina kroz filter (5).
A method as claimed in anyone of claims 8 to 13, wherein only some of the filters (5) of the filter apparatus (3) at a time are separated for cleaning, the rest of the filters (5) in the filter apparatus (3) remaining in use for filtering product gas. 
Postupak prema bilo kojem od zahtjeva 8 do 13, naznačen time da su samo neki od filtera (5) aparature za filtriranje (3) odvojeni za čišćenje, a ostatak filtera (5) u aparaturi za filtriranje (3) ostaje u uporabi za filtriranje proizvodnog plina.
Composition according to claim 1 or 2, characterized in that corosolic acid and ellagitannins are contained in a vegetable extract of Banaba (Lagerstroemia speciosa L .), preferably a dry Banaba (Lagerstroemia speciosa L.) leaf extract. 
Pripravak za upotrebu prema patentnom zahtjevu 1 ili 2, naznačen time da su korozilna kiselina i elagitanini sadržani u ekstraktu biljke Banaba (Lagerstroemia speciosa), po mogućnosti suhom ekstraktu Banabinog lista.
Composition according to claim 4 wherein lignans are extracted from flax plant seeds. 
Pripravak za upotrebu prema patentnom zahtjevu 4, pri čemu se lignani ekstrahiraju iz sjemena biljke lana.
Composition according to any one of claims from 1 to 6, characterized in that it is a food supplement, a dietetic product, a medicine, a herbal product or a nutritional supplement. 
Pripravak za upotrebu prema bilo kojem od patentnih zahtjeva od 1 do 6, naznačen time da je dodatak prehrani, dijetetski proizvod, lijek, biljni proizvod ili hranjivi dodatak.
the first fragment is a toxin A repeating domain fragment; 
prvi fragment je fragment ponavljane domene toksina A;
the second fragment is a toxin B repeating domain fragment; 
drugi fragment je fragment ponavljane domene toksina B;
An immunogenic composition according to claim 10 wherein the first proximal end is within a short repeat and/or the second proximal end is within a short repeat. 
Imunogeni pripravak u skladu s patentnim zahtjevom 10, naznačen time što se prvi proksimalni kraj nalazi u kratkom ponavljanju i/ili drugi proksimalni kraj se nalazi u kratkom ponavljanju.
the first fragment comprises a first proximal end within a first repeat portion; 
prvi fragment sadrži prvi proksimalni kraj unutar prvog ponavljanog dijela;
The wear member according to anyone of the preceding claims, characterized that an opening (101) for receiving a lock (16) to secure the wear member (14) to the base (12) is provided. 
Potrošni dio u skladu s patentnim zahtjevom 1, naznačen time što sadrži otvor (101) za prihvaćanje brave (16) radi osiguravanja potrošnog dijela (14) na podnožje (12).
a base (12) fixed to the excavating equipment; 
podnožje (12), pričvršćeno na opremu za jaružanje;
The pharmaceutical composition for use according to claim 1, wherein the pharmaceutical composition contains 100 mg of Compound 1. 
Farmaceutski sastav za upotrebu prema zahtjevu 1, gdje ovaj farmaceutski sastav sadrži 100 mg Spoja 1.
The pharmaceutical composition for use according to claim 1, wherein the other desired therapeutic comprises an additional agent selected from a mucolytic agent, bronchodilator, an antibiotic, an anti-infective agent, an antiinflammatory agent, a CFTR modulator other than Compound 1, or a nutritional agent. 
Farmaceutski sastav za upotrebu prema zahtjevu 1, gdje drugi poželjan terapeutik obuhvaća dodatni agens odabran iz grupe koju čine mukolitski agens, bronhodilator, antibiotik, protuinfekcijski agens, protuupalni agens, modulator CFTR različit od Spoja 1, ili hranidbeni agens.
The pharmaceutical composition for use according to claim 4, wherein the other desired therapeutic is a CFTR modulator other than compound 1. 
Farmaceutski sastav za upotrebu prema zahtjevu 4, gdje drugi poželjan terapeutik predstavlja neki modulator CFTR, koji se razlikuje od spoj 1.
An isolated monoclonal antibody or antigen-binding fragment thereof specific for coagulation factor XI (fXI) and which binds fXI competitively with antibody having the variable light chain (VL) of SEQ ID NO: 1 and the variable heavy chain (VH) of SEQ ID NO: 3, wherein: 
Izolirano monoklonsko protutijelo ili njegov fragment koji se veže na antigen, naznačeno/naznačen time, da je specifično/specifičan za koagulacijski faktor XI (fXI) i koje/koji konkurira za vezanje faktora XI (fXI) s jednim protutijelom koje ima varijabilni laki lanac (VL) od SEQ ID NO: 1 i varijabilni teški lanac (VH) od SEQ ID NO: 3, pri čemu:
The isolated monoclonal antibody of claim 1, wherein the amino acid sequence of the VL is at least 95% identical to SEQ ID NO: 1. 
Izolirano monoklonsko protutijelo prema zahtjevu 1, naznačeno time, da je aminokiselinska sekvenca od VL najmanje 95% identična sa SEQ ID NO: 1.
The isolated monoclonal antibody of claim 1, wherein the amino acid sequence of the VL consists of SEQ ID NO: 1. 
Izolirano monoklonsko protutijelo prema zahtjevu 1, naznačeno time, da se aminokiselinska sekvenca od VL sastoji od SEQ ID NO: 1.
A composition comprising the antibody of any one of claims 1-10 or the immunoconjugate of claim 11 or claim 12 and a pharmaceutically acceptable carrier. 
Sastav, naznačen time, da obuhvaća protutijelo iz bilo kojeg od zahtjeva 1 do 10 ili imunokonjugat iz zahtjeva 11 ili zahtjeva 12 te farmaceutski prihvatljiv nosač.
An isolated nucleic acid molecule encoding the monoclonal antibody of any one of claims 1-10. 
Izolirana molekula nukleinske kiseline, naznačena time, da ona kodira monoklonsko protutijelo iz bilo kojeg od zahtjeva 1 do 10.
The isolated nucleic acid molecule of claim 14, wherein the nucleotide sequence encoding the VL of the monoclonal antibody comprises SEQ ID NO: 2. 
Izolirana molekula nukleinske kiseline prema zahtjevu 14, naznačena time, da nukleotidna sekvenca koja kodira VL od monoklonskog protutijela, obuhvaća SEQ ID NO: 2.
The isolated nucleic acid molecule of claim 14 or claim 15, wherein the nucleotide sequence encoding the VH of the monoclonal antibody comprises SEQ ID NO: 4. 
Izolirana molekula nukleinske kiseline prema zahtjevu 14 ili zahtjevu 15, naznačena time, da nukleotidna sekvenca koja kodira VH od monoklonskog protutijela, obuhvaća SEQ ID NO: 4.
The monoclonal antibody, the immunoconjugate or the composition for use according to claim 20, wherein the subject in need of treatment is a subject with pathological activation of fXI. 
Monoklonsko protutijelo, imunokonjugat ili sastav za uporabu prema zahtjevu 20, naznačeni time, da se kod pojedinca kojemu treba liječenje, radi o pojedincu kojemu je patološki aktiviran fXI.
The monoclonal antibody, the immunoconjugate or the composition for use according toclaim 20 or claim 21, wherein in the method the inhibitory amount of the monoclonal antibody, immunoconjugate or composition is an amount sufficient to inhibit activation of fXI by at least 50%. 
Monoklonsko protutijelo, imunokonjugat ili sastav za uporabu prema zahtjevu 20 ili zahtjevu 21, naznačeni time, da je inhibicijska količina monoklonskog protutijela, imunokonjugata ili sastava u postupku, ona količina koja je dovoljna za inhibiranje aktivacije fXI od najmanje 50%.
The monoclonal antibody, the immunoconjugate or the composition for use according to any one of claims 20-22, wherein in the method the antibody, immunoconjugate or composition is administered to the subject by parenteral administration. 
Monoklonsko protutijelo, imunokonjugat ili sastav za uporabu prema bilo kojem od zahtjeva 20 do 22, naznačeni time, da se u postupku, protutijelo, imunokonjugat ili sastav daju pojedincu putem parenteralne primjene.
The monoclonal antibody, the immunoconjugate or the composition for use according to claim 23, wherein in the method the antibody, immunoconjugate or composition is administered by injection. 
Monoklonsko protutijelo, imunokonjugat ili sastav za uporabu prema zahtjevu 23, naznačeni time, da se u postupku, protutijelo, imunokonjugat ili sastav daju pomoću injekcije.
The monoclonal antibody, the immunoconjugate or the composition for use according to any one of claims 20-24, wherein in the method the antibody, immunoconjugate or composition is administered daily or bi-weekly. 
Monoklonsko protutijelo, imunokonjugat ili sastav za uporabu prema bilo kojem od zahtjeva 20 do 24, naznačeni time, da se u postupku, protutijelo, imunokonjugat ili sastav primjenjuju dnevno ili dvotjedno.
The monoclonal antibody, the immunoconjugate or the composition for use according to any one of claims 20-25, wherein in the method the antibody is administered at a dose of about 0.1 to about 10 mg/kg. 
Monoklonsko protutijelo, imunokonjugat ili sastav za uporabu prema bilo kojem od zahtjeva 20 do 25, naznačeni time, da se u postupku, protutijelo daje u dozi od oko 0,1 do oko 10 mg/kg.
Use of the antibody of any one of claims 1-10, the immunoconjugate of claim 11 or claim 12, or the composition of claim 13 in the manufacture of a medicament for preventing or treating thrombosis or thromboembolism. 
Uporaba protutijela iz bilo kojeg od zahtjeva 1 do 10, imunokonjugata iz zahtjeva 11 ili zahtjeva 12, ili sastava iz zahtjeva 13, naznačena time, da služi u proizvodnji lijeka za prevenciju ili liječenje tromboze ili tromboembolizma.
An apparatus (300) according to claim 1 or 2, wherein said upstream pair (220) of a stator and a rotor is downstream of a first pair (210) of a stator and a rotor. 
Uređaj (300) u skladu s patentnim zahtjevom 1 ili 2, naznačen time što se navedeni uzvodni par (220) statora i rotora nalazi nizvodno od prvog para (210) statora i rotora.
An apparatus (300) according to any one of the preceding claims, wherein the rotor and stator of at least one pair of a rotor and a stator (210, 220, 230, 240) have at least two rows of opposed toothed rims. 
Uređaj (300) u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što rotor i stator u najmanje jednom paru rotora i statora (210, 220, 230, 240) imaju najmanje dva reda suprotno nazubljenih obruča.
An apparatus (300) according to any one of the preceding claims, wherein the gas outlet (11) of the injector (1) is located proximate an inner toothed rim of the first pair (210) of a rotor and a stator. 
Uređaj (300) u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što se izlaz za plin (11) injektora (1) nalazi u blizini unutarnjeg nazubljenog obruča prvog para (210) rotora i statora.
An apparatus (300) according to any one of the preceding claims comprising a back-pressure regulator arranged in the flow path of product downstream of the mixing apparatus. 
Uređaj (300) u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što sadrži regulator povratnog tlaka koji se nalazi u putu tečenja proizvoda nizvodno od uređaja za miješanje.
An apparatus (300) according to any one of the preceding claims comprising at least three pairs (210, 220, 240) of a stator and a rotor, and up to eight pairs of a stator and a rotor. 
Uređaj (300) u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što sadrži najmanje tri para (210, 220, 240) statora i rotora, pa do osam parova statora i rotora.
is selected from or wherein 
je izabran od ili pri čemu
A pharmaceutical composition comprising a pharmaceutical excipient and an antivirally-effective amount of the compound of any one of claims 1 or 2. 
Farmaceutski sastav koji obuhvaća farmaceutsku pomoćnu tvar i antivirusno učinkovitu količinu spoja prema bilo kojem od zahtjeva 1 ili 2.